XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

PHASE3WithdrawnINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2006

Study Completion Date

January 31, 2008

Conditions
Brain EdemaBrain Tumor
Interventions
DRUG

hCRF

hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking

DRUG

placebo hCRF

placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking

Trial Locations (26)

10021

Weill Medical College of Cornell University, New York

14226

Dent Neurologic Institute, Amherst

27106

Wake Forest University, Winston-Salem

30322

Winship Cancer Institute, Emory University, Atlanta

33612

Moffitt Cancer Center and Research, Tampa

37232

Vanderbilt University Medical Center, Nashville

38103

Methodist Healthcare - University Hospital, Memphis

43210

University Hematology Oncology Care, LLC, Cincinnati

The Ohio State University, Columbus

45220

Good Samaritan Hospital, Cincinnati

48604

Field Neurosciences Institute, Saginaw

53792

University of Wisconsin, Madison

60201

Evanston Northwestern Healthcare, Evanston

60611

Northwestern University, Feinberg School of Medicine, Chicago

80045

University of Colorado Cancer Center, Aurora

85013

Barrow Neurological Institute, Phoenix

92093

UC San Diego Cancer Center, La Jolla

92658

Hoag Memorial Hospital Presbyterian, Newport Beach

94305

Stanford University Medical Center, Palo Alto

95817

UC Davis Medical Center, Sacramento

97210

Oregon Clinic, Portland

02215

Beth Israel Deaconess Med Center, Boston

07450

Neurology Group of Bergen County, Ridgewood

53226-3596

Medical College of Wisconsin, Milwaukee

T6G1ZT

Cross Cancer Institute, Edmonton

K1H 1C4

Ottawa Regional Cancer Centre, Ottawa

All Listed Sponsors
collaborator

Neurobiological Technologies

INDUSTRY

lead

Celtic Pharma Development Services

INDUSTRY